0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

CLINICAL USE OF THE ANTIBIOTIC CHLORAMPHENICOL (CHLOROMYCETIN®)

JOSEPH E. SMADEL, M.D.
JAMA. 1950;142(5):315-318. doi:10.1001/jama.1950.02910230017004.
Text Size: A A A
Published online

It is two years since the first reports appeared dealing with the new antibiotic choloramphenicol (chloromycetin®). These first papers1 described laboratory experiments in which the antibiotic was shown to inhibit the growth in vitro of a wide range of bacteria and, of greater interest at that time, to have a chemotherapeutic effect in a number of experimental rickettsial and virus infections. In addition, chloramphenicol was found to have two other characteristics which promised to make it useful in the treatment of patients. These were (1) its low toxicity for animals and (2) its capacity to elicit as satisfactory results when given by the oral route as by the parenteral route. It was quickly shown that the new drug was essentially nontoxic for normal men and that relatively simple technics revealed the presence of appreciable levels of active drug in the blood and urine of such persons following oral administration

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();